BACKGROUND: Pulmonary rehabilitation (PR) is the primary, non-pharmacologic treatment for people with chronic lung disease. Access to PR is limited and individuals often face barriers to participation. To increase access, an Alternate Program (AP) with reduced commitment was created. PURPOSE: To evaluate the AP in terms of patient characteristics, within-subject effects on patient reported outcomes, discharge pathways and patient acceptability. METHODS: Participants completed questionnaires and physical tests pre- and post-AP. Data are presented as means and standard deviations, medians and 25th-75th percentiles, or frequencies as appropriate. Differences from pre- to post-program were analyzed with paired t-tests or Wilcoxon signed rank tests. RESULTS : A total of 34 participants were enrolled in the program. Participants were mostly men (65%) with a mean age of 67 years. The majority of participants (62%) had an obstructive lung disease and/or asthma. Statistically significant improvements from pre- to post-program were found for Canadian Occupational Performance Measure (COPM) performance (1.2 +/-- 1.7 points, p < 0.001), COPM satisfaction (1.5 +/- 2.1 points, p < 0.001), 6-Minute Walk Test (6MWT) 36.0 +/- 46.0 m, p < 0.001) and Self-Efficacy for Exercise (SEE) scale (1.1 +/- 2.0 points, p = 0.004). A large percentage (46%) of patients transitioned from AP to full PR; most were satisfied (14%) or very satisfied (79%) with the program. CONCLUSIONS: The AP may be a reasonable alternative when individuals are unable to access traditional PR, allowing increased access to treatment and improve exercise self-efficacy allowing them to gain access to traditional PR.
Importance:Given its recurrent nature and burden, major depressive disorder (MDD) warrants reliable methods of relapse prediction. Objective:To determine whether actigraphy-derived parameters, measured over 1 to 2 years, are associated with relapse. Design, Setting, and Participants:This was an observational cohort study with data collection from July 2016 to January 2019. The setting was multicentric. A referred sample of participants from outpatient psychiatric and primary care clinics across Canada were followed up for 1 to 2 years. Participants had a diagnosis of MDD and Montgomery-Åsberg Depression Rating Scale (MADRS) score less than or equal to 14 at baseline. Exposures:Actigraphy-derived parameters measured over 1 to 2 years. Main Outcome and Measures:The primary outcome was relapse, defined as any of the following: MADRS score greater than or equal to 22 for 2 consecutive weeks, psychiatric hospitalization, emergence of suicidal intent or behavior, or antidepressant treatment escalation-all adjudicated by an independent panel. Continuous actigraphy data were averaged every 2 weeks. Results:From a referred sample of 102 adults, 93 participants (mean [SD] age, 39.1 [12.7] years; 58 female [62%]) contributed approximately 32 000 complete actigraphy days (median, 46 weeks). In Cox models adjusted for age, sex, season, and baseline MADRS score, baseline lower sleep regularity (hazard ratio [HR], 0.46; 95% CI, 0.28-0.74; P = .002), lower relative amplitude (RA; HR, 0.45; 95% CI, 0.29-0.70; P < .001), lower sleep efficiency (HR, 0.57; 95% CI, 0.38-0.85; P = .005), higher wake after sleep onset (HR, 1.77; 95% CI, 1.12-2.80; P = .01), and higher nighttime activity (HR, 1.86; 95% CI, 1.32-2.62; P < .001) were associated with relapse. In time-varying models, greater composite phase deviation (HR, 1.76; 95% CI, 1.04-2.98; P = .04) and lower RA (HR, 0.45; 95% CI, 0.21-0.97; P = .046) were associated with relapse, with RA remaining significant even after adjusting for concurrent MADRS scores (HR, 0.60; 95% CI, 0.36-0.98; P = .04). Actigraphy significantly differentiated individuals experiencing relapse from those with an ultrastable (MADRS score <14 throughout) and unstable (transient MADRS score, 14-22 without relapse) clinical course. Conclusions and Relevance:Actigraphy measures of sleep phase variability and daily activity amplitude were associated with depressive relapse, supporting actigraphy as a potential scalable biomarker to identify high-risk individuals and enable timely, personalized relapse prevention in MDD.
OBJECTIVE:The International Neuropsychological Society (INS) Justice and Equity Subcommittee initiated a survey of neuropsychological academic training programs, clinical practices, and research across Africa, examining respondents' interest in collaboration and their views on resources needed to advance the field. METHOD:This quantitative, cross-sectional study employed chain-referral sampling at higher education institutions identified via uniRank. Of the 1,244 institutions screened, 241 offered psychology or psychiatry coursework. A multilingual cover letter and survey link (English, Swahili, Arabic, French, Portuguese, Spanish) were distributed, yielding 42 respondents from 17 of 54 countries (≈31.5% country response rate). RESULTS:Most respondents were clinical psychologists or neuropsychologists and reported 1-5 neuropsychologists per country. Neuropsychologists' roles included cognitive assessment, research, teaching, and assisting in neurological diagnoses, primarily using tests developed outside Africa. Current research centered on the neuropsychological effects of psychiatric disorders, infectious diseases (e.g., HIV, cerebral malaria), and neurodevelopmental disorders, with future focus areas identified as traumatic brain injury and epilepsy. Educational and training opportunities remain limited. Key barriers to program development included insufficient numbers of trained neuropsychologists, clinical training sites, and employment prospects. Despite this, there is strong interest in collaboration to accelerate the development of neuropsychology and neurosciences, given the heavy burden of neurological disease. CONCLUSION:To foster growth, efforts must target the creation of academic and clinical training pathways and the adaptation, standardization, and norming of assessment tools tailored to African populations. There exist ample impactful avenues for individual and organizational collaboration or support to further the global development of neuropsychology.
Introduction Survivors of intensive care unit (ICU) admission and their families frequently experience persistent physical, cognitive and psychological impairments following critical illness, collectively described as post-intensive care syndrome (PICS) and post-intensive care syndrome-family (PICS-F). These sequelae often emerge during the recovery period after hospital discharge and may affect long-term functioning and quality of life. Social connectivity—the extent to which individuals maintain meaningful social relationships and supportive interactions—has been associated with improved health outcomes in several populations. This scoping review aims to map the existing literature describing social connectivity among ICU survivors and their families and examine how it has been studied in relation to recovery outcomes.Methods and analysis This scoping review will be conducted using the Joanna Briggs Institute methodology for scoping reviews and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. MEDLINE, EMBASE, CINAHL and PsycINFO will be searched from database inception to December 2025 without language restrictions. Studies examining social connectivity in relation to PICS or PICS-F among adult ICU survivors or their family members will be included. Data will be extracted independently using a standardised charting form and summarised descriptively.Ethics and dissemination Ethical approval is not required because this study synthesises previously published literature. Findings will be disseminated through publication in a peer-reviewed journal and may inform future research and patient- and family-centred strategies to support recovery after critical illness.
BACKGROUND:For patients with immune thrombocytopenia (ITP), a critical bleed, such as intracranial hemorrhage or bleeding causing hemodynamic instability, requires urgent treatment to rapidly raise the platelet count and restore hemostasis. There is no standardized approach to this hematologic emergency. OBJECTIVE:The McMaster ITP Emergency Management Guideline Group developed evidence-informed recommendations for the management of a critical bleed in adults and children with ITP. METHODS:The guideline panel included 5 clinical experts in adult ITP, 3 clinical experts in pediatric ITP, 2 emergency department physicians, 1 emergency department nurse, 2 methodologists, and 4 patient partners. To inform recommendations, the guideline team conducted a multicenter retrospective cohort study and systematic reviews. The panel used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to rate the certainty in the evidence and GRADE evidence-to-decision framework to formulate recommendations. RESULTS:Given the life-threatening nature or significant morbidity associated with the condition, despite low or very low certainty in the evidence, the panel made strong recommendations for the combined use of high-dose corticosteroids, high-dose IV immunoglobulin (IVIG), platelet transfusions, tranexamic acid, and thrombopoietin receptor agonists (TPO-RAs) for the treatment of adults or children with a critical ITP bleed. The panel made a conditional recommendation for urgent splenectomy when other treatments have failed and, due to the risk of thrombosis, a conditional recommendation against the use of recombinant factor VIIa. CONCLUSIONS:Motivated by the life-threatening nature of the condition, the panel made strong recommendations for the combined use of high-dose corticosteroids, high-dose IVIG, platelet transfusions, tranexamic acid, and TPO-RAs for the emergency management of adults and children with a critical ITP bleed.